approaches to topical treatment (1) (1) manipulate the barrier (2) (2) direct drugs to viable skin...
TRANSCRIPT
![Page 1: Approaches to topical treatment (1) (1) Manipulate the barrier (2) (2) Direct drugs to viable skin tissues (3) (3) Skin treatment for systemic conditions](https://reader036.vdocument.in/reader036/viewer/2022062423/5697bfea1a28abf838cb7261/html5/thumbnails/1.jpg)
Approaches to topical treatmentApproaches to topical treatment
(1)
(1) Manipulate the barrier(2)
(2) Direct drugs to viable skin tissues
(3)
(3) Skin treatment for systemicconditions
![Page 2: Approaches to topical treatment (1) (1) Manipulate the barrier (2) (2) Direct drugs to viable skin tissues (3) (3) Skin treatment for systemic conditions](https://reader036.vdocument.in/reader036/viewer/2022062423/5697bfea1a28abf838cb7261/html5/thumbnails/2.jpg)
Target regions of topical treatmentTarget regions of topical treatment
Interfacial boundries Penetration routes Some treatments
(1) Surface Drug dissolves 1. Camouflagediffuses, releases 2. Protective layerfrom vehicle 3. Insect repellant
4. Antimicrobial
(2) Stratum Partition/diffusion 1. Emoliency corneum stratum corneum 2. Keratosis
(3) Appendages Piloseba- Ecrine 1. Antiperspirantseous unit gland 2. Exfolient
3. Antibiotic4. Depilatory
![Page 3: Approaches to topical treatment (1) (1) Manipulate the barrier (2) (2) Direct drugs to viable skin tissues (3) (3) Skin treatment for systemic conditions](https://reader036.vdocument.in/reader036/viewer/2022062423/5697bfea1a28abf838cb7261/html5/thumbnails/3.jpg)
Interfacial boundries Penetration routes Some treatments
(5) Circulation Removal via 1. Transdermal deliverycirculation 2. Nitroglycerin
(4) Viable Partition/diffusion epidermis viable epidermis
1. Antiinflammatory2. Anaesthetic
Dermis Partition/diffusion 3. Antipruritic corneum dermis 4. Antihistamine
(con’t)
![Page 4: Approaches to topical treatment (1) (1) Manipulate the barrier (2) (2) Direct drugs to viable skin tissues (3) (3) Skin treatment for systemic conditions](https://reader036.vdocument.in/reader036/viewer/2022062423/5697bfea1a28abf838cb7261/html5/thumbnails/4.jpg)
Sample Question
• Ms. Smiley consulted pharmacist Dr. Thoughtful for an insect repellant to be used on her 2 year old Bliss who has a dry skin problem. To maintain Bliss’s skin smooth and moist, Ms. Smiley has been applying Aquophilic (a water in oil cream). She wanted to know if it is OK to apply insect repellent on the skin that is moisturized with the cream.
![Page 5: Approaches to topical treatment (1) (1) Manipulate the barrier (2) (2) Direct drugs to viable skin tissues (3) (3) Skin treatment for systemic conditions](https://reader036.vdocument.in/reader036/viewer/2022062423/5697bfea1a28abf838cb7261/html5/thumbnails/5.jpg)
Transdermal drug delivery systems (TDDS)
• Pharmaceutical formulations that are designed to deliver an active drug across the skin into systemic circulation.
• Substances that possess both aqueous and lipid solubility characteristics are good candidates for diffusion through skin.
• Types of transdermal control released systems.
1. Membrane controlled systems.
2. Adhesive diffusion - controlled systems.
3. Matrix controlled systems.
![Page 6: Approaches to topical treatment (1) (1) Manipulate the barrier (2) (2) Direct drugs to viable skin tissues (3) (3) Skin treatment for systemic conditions](https://reader036.vdocument.in/reader036/viewer/2022062423/5697bfea1a28abf838cb7261/html5/thumbnails/6.jpg)
TDD Patch Construction
MatrixNitro-Dur (Key Pharma) Reservoir
E.g.Transderm-NitroTM
(Ciba/Pharmaco)
Drug-in-AdhesiveMulti-LayerDeponitTM
(Pharma-Schwartz)
Drug-in-Adhesive Single-Layer
Nitrodisc (Searle Pharma)
Backing Drug Membrane Adhesive Liner/Skin
![Page 7: Approaches to topical treatment (1) (1) Manipulate the barrier (2) (2) Direct drugs to viable skin tissues (3) (3) Skin treatment for systemic conditions](https://reader036.vdocument.in/reader036/viewer/2022062423/5697bfea1a28abf838cb7261/html5/thumbnails/7.jpg)
Sample Question
• Which of the patches outlined in the cartoon can be cut to customize dose according to patient need.
![Page 8: Approaches to topical treatment (1) (1) Manipulate the barrier (2) (2) Direct drugs to viable skin tissues (3) (3) Skin treatment for systemic conditions](https://reader036.vdocument.in/reader036/viewer/2022062423/5697bfea1a28abf838cb7261/html5/thumbnails/8.jpg)
Why transdermal drug delivery?
• Continous IV administration at a constant rate of infusion is a superior mode of drug delivery
• IV administration avoids hepatic first-pass metabolism and maintain constant therapeutic drug levels in the body
• TDD can closely duplicate continuous IV fusion. Hence it is helpful in delivering drugs that undergo significant first pass metabolism and/or have narrow therapeutic index
![Page 9: Approaches to topical treatment (1) (1) Manipulate the barrier (2) (2) Direct drugs to viable skin tissues (3) (3) Skin treatment for systemic conditions](https://reader036.vdocument.in/reader036/viewer/2022062423/5697bfea1a28abf838cb7261/html5/thumbnails/9.jpg)
Sample Question
• Ibuprofen (Motrin) is usually administered 300 mg every 6 hours for acute muscle pain/inflamation. Orally administered ibuprofen may cause gastric discomfort. Although ibuprofen is lipophilic and might have good skin permeability, transdermal delivery is not an alternative for ibuprofen why?
![Page 10: Approaches to topical treatment (1) (1) Manipulate the barrier (2) (2) Direct drugs to viable skin tissues (3) (3) Skin treatment for systemic conditions](https://reader036.vdocument.in/reader036/viewer/2022062423/5697bfea1a28abf838cb7261/html5/thumbnails/10.jpg)
Principles of diffusion through membranesPrinciples of diffusion through membranes
Homogenousmembrane
Aqueouspores
Cellulosefibres
(1) Diffusion - random molecular motion. Must have concentration gradient.
![Page 11: Approaches to topical treatment (1) (1) Manipulate the barrier (2) (2) Direct drugs to viable skin tissues (3) (3) Skin treatment for systemic conditions](https://reader036.vdocument.in/reader036/viewer/2022062423/5697bfea1a28abf838cb7261/html5/thumbnails/11.jpg)
Donor Receptor
CdC1
C2
Cr
h
D
C0 Donorsolution P
erm
ea
ble
me
mb
ran
e
Blo
od
K
![Page 12: Approaches to topical treatment (1) (1) Manipulate the barrier (2) (2) Direct drugs to viable skin tissues (3) (3) Skin treatment for systemic conditions](https://reader036.vdocument.in/reader036/viewer/2022062423/5697bfea1a28abf838cb7261/html5/thumbnails/12.jpg)
h
CCSD
dt
dMJ 21
Where, dM = change in mass transferred dt in change of time t
D = diffusion constantC1 = concentration in donor compartmentC2 = concentration in receptor compartmentS = surface area of membrane
Since K = C1 = C2
Cd Cr
dM
dt
SDK C C
hd r
Under sink conditions and rearranging all constants,
M PSC tr d Where, P = permeability constant
Fick’s law of diffusionFick’s law of diffusion
![Page 13: Approaches to topical treatment (1) (1) Manipulate the barrier (2) (2) Direct drugs to viable skin tissues (3) (3) Skin treatment for systemic conditions](https://reader036.vdocument.in/reader036/viewer/2022062423/5697bfea1a28abf838cb7261/html5/thumbnails/13.jpg)
Sample Questions
• What is the flux of drug entering systemic circulation from a patch having a surface area of 10 cm2, containing 50 mg of drug. The average skin thickness of the patient is 7mm. Diffusion coefficient of the skin is 1 x 10-5 cm/min.
• Using the above information, calculate the permeability coefficient of the drug across skin.
• What is the total amount of drug delivered from the patch into blood stream in 12 hours.
![Page 14: Approaches to topical treatment (1) (1) Manipulate the barrier (2) (2) Direct drugs to viable skin tissues (3) (3) Skin treatment for systemic conditions](https://reader036.vdocument.in/reader036/viewer/2022062423/5697bfea1a28abf838cb7261/html5/thumbnails/14.jpg)
Complex diffusional barriersComplex diffusional barriers
Stratum corneum
Epidermis
Dermis
Subcutaneous
nKnDKDKD
tP
1...
22
1
11
11t
R
Where, Rt = Total diffusing resistancePt = Thickness – weighted permeability coeff.
![Page 15: Approaches to topical treatment (1) (1) Manipulate the barrier (2) (2) Direct drugs to viable skin tissues (3) (3) Skin treatment for systemic conditions](https://reader036.vdocument.in/reader036/viewer/2022062423/5697bfea1a28abf838cb7261/html5/thumbnails/15.jpg)
Parrallel
dM
dt
SDK C C
hd r
FOR EACH
![Page 16: Approaches to topical treatment (1) (1) Manipulate the barrier (2) (2) Direct drugs to viable skin tissues (3) (3) Skin treatment for systemic conditions](https://reader036.vdocument.in/reader036/viewer/2022062423/5697bfea1a28abf838cb7261/html5/thumbnails/16.jpg)
Sample questions
• Flux of a drug Y across the stratum corneum is 0.1g/cm2 hr and the flux across the rest of epidermis, dermis and sub-dermis is 0.5, 2 and 1.5 g/cm2 hr, respectively. Calculate the total diffusional resistance across the skin for drug Y.
• The flux of drug Y across hair follicles, sweat glands and sebaceous glands is 10-5, 10-6 and 10-5 g/cm2 hr. What is the total appendageal flux of drug Y.
• What is the total flux of drug Y across the skin, both transdermal and trans-appendageal combined.
![Page 17: Approaches to topical treatment (1) (1) Manipulate the barrier (2) (2) Direct drugs to viable skin tissues (3) (3) Skin treatment for systemic conditions](https://reader036.vdocument.in/reader036/viewer/2022062423/5697bfea1a28abf838cb7261/html5/thumbnails/17.jpg)
Factors influencing the rate of percutaneousdiffusion
Factors influencing the rate of percutaneousdiffusion
1. Diffusant solubility (C0)
2. Partition coefficient (K)
3. pH variation (K)
4. Co-solvents (K and C0)
5. Surface activity and micellization (C0)
6. Complexation (K)
7. Diffusivity (D)
![Page 18: Approaches to topical treatment (1) (1) Manipulate the barrier (2) (2) Direct drugs to viable skin tissues (3) (3) Skin treatment for systemic conditions](https://reader036.vdocument.in/reader036/viewer/2022062423/5697bfea1a28abf838cb7261/html5/thumbnails/18.jpg)
Sample Questions
• Diffusion coefficient of drug A is 10-6 and the diffusion coefficient of drug B is 10-4 if all the other parameters are constant, which drug is likely to have better flux across skin.
• If the surface area of patch A is 2 cm2 and that of patch B is 4 cm2, which of these two patches is likely to have more drug delivered across skin and by what extent.
• Log K of drug X is -1, log K of drug Y is 2 and that of drug Z is 4, which is more likely to have better transdermal permeability and which is more likely to have better trans-appendageal permeability.
![Page 19: Approaches to topical treatment (1) (1) Manipulate the barrier (2) (2) Direct drugs to viable skin tissues (3) (3) Skin treatment for systemic conditions](https://reader036.vdocument.in/reader036/viewer/2022062423/5697bfea1a28abf838cb7261/html5/thumbnails/19.jpg)
Factors that effect percutaneous absorptionFactors that effect percutaneous absorption
Biological factorsBiological factors
1. Skin age
2. Skin condition
3. Regional skin sites
4. Skin metabolism
5. Circulatory effects
![Page 20: Approaches to topical treatment (1) (1) Manipulate the barrier (2) (2) Direct drugs to viable skin tissues (3) (3) Skin treatment for systemic conditions](https://reader036.vdocument.in/reader036/viewer/2022062423/5697bfea1a28abf838cb7261/html5/thumbnails/20.jpg)
Hints
• Know how each of these factors affect skin permeability
![Page 21: Approaches to topical treatment (1) (1) Manipulate the barrier (2) (2) Direct drugs to viable skin tissues (3) (3) Skin treatment for systemic conditions](https://reader036.vdocument.in/reader036/viewer/2022062423/5697bfea1a28abf838cb7261/html5/thumbnails/21.jpg)
Physicochemical factorsPhysicochemical factors
1. Skin hydration
2. Drug/skin binding
3. Temperature
4. Penetration enhancers
5. Drug/vehicle interaction
![Page 22: Approaches to topical treatment (1) (1) Manipulate the barrier (2) (2) Direct drugs to viable skin tissues (3) (3) Skin treatment for systemic conditions](https://reader036.vdocument.in/reader036/viewer/2022062423/5697bfea1a28abf838cb7261/html5/thumbnails/22.jpg)
Hints
• Know how each of these factors affect skin permeability
![Page 23: Approaches to topical treatment (1) (1) Manipulate the barrier (2) (2) Direct drugs to viable skin tissues (3) (3) Skin treatment for systemic conditions](https://reader036.vdocument.in/reader036/viewer/2022062423/5697bfea1a28abf838cb7261/html5/thumbnails/23.jpg)
• Daily dose (< 20 mg/day)• Half-life (10 hours or less)• Molecular weight (< 500 Daltons)• Melting point (< 200 oC)• Skin permeability• Lipid solubility
[partition coefficient (Log P) between –1.0 and 4]
• Toxicology profile(non-irritating and non-sensitizing to skin)
Attributes of a Passive TDD Drug Candidate
![Page 24: Approaches to topical treatment (1) (1) Manipulate the barrier (2) (2) Direct drugs to viable skin tissues (3) (3) Skin treatment for systemic conditions](https://reader036.vdocument.in/reader036/viewer/2022062423/5697bfea1a28abf838cb7261/html5/thumbnails/24.jpg)
Hints
• Know how each of these factors affect skin permeability